KYTX Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action LawsuitRADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyverna, Sun Communities, DMC Global, and Marqeta and Encourages Investors to Contact the FirmNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (
NASDAQKYTX), Sun Communities
NYSE: SUINYSESUI)
(NASDAQ: BOOMNASDAQBOOM
, and Marqeta, Inc. (NASDAQ:MQNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX), if they purchased the Company’s shares pursuant and/or traceable to the Company’s registration statement issued in connection with its February 2024 initial public offering (“IPO”). This action is pending in the United States District Court for the Northern District of California.
KYTX Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action LawsuitRADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
KYTX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action LawsuitRADNOR, PA - February 2, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options
KYTX Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action LawsuitRADNOR, PA - February 1, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Important February 7, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Securities Fraud Class Action LawsuitRADNOR, PA - January 30, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action LawsuitRADNOR, PA - January 29, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyverna, Five9, DMC Global, and Marqeta and Encourages Investors to Contact the FirmNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (
NASDAQKYTX), Five9, Inc.
NASDAQ: FIVNNASDAQFIVN)
(NASDAQ: BOOMNASDAQBOOM
, and Marqeta, Inc. (NASDAQ:MQNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. (KYTX) Securities Class Action LawsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. (KYTX) Securities Class Action LawsRADNOR, PA - January 28, 2025 (NEWMEDIAWIRE) -The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.RADNOR, PA - January 26, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (
NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Kyverna Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Class Action Against KYTXSAN DIEGO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (
NASDAQKYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
